Bifidobacterium breve 用于 Irritable Bowel Syndrome (IBS)
DLimited data from small studies. Preliminary evidence for symptom improvement.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
结论
Limited data from small studies. Preliminary evidence for symptom improvement.
Key Study Findings
Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Other
n=1098
8 weeks
Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None
vs: None (single-arm open-label)
Outcome: Treatment success for abdominal pain and bloating
效果: 73% pain, 81.9% bloating success at T1
<0.001
研究人群: IBS patients from 52 Italian gastroenterologists
Randomized Controlled Trial
n=61
8 weeks
Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None
vs: Placebo
Outcome: IBS-SSS symptom severity score change
效果: None
None
研究人群: Patients with moderate-severe diarrhea-predominant IBS
Randomized Controlled Trial
4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g
vs: Placebo
Outcome: Constipation symptoms
效果: None
P = 0.005
研究人群: IBS patients
Review
Postbiotics: A new member in the biotics family.
Dose: None
vs: None
Outcome: Clinical applications overview
效果: None
None
研究人群: General population (review)
In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None
vs: None
Outcome: Colitis severity
效果: None
None
研究人群: Crohn's disease patients
Key Statistics
2
研究数量
150
受试者
↑
Positive
D
等级
Referenced Papers
Microbiome research reports
2025
16 次引用
Beneficial microbes
2025
Frontiers in nutrition
2025
The Yale journal …
2024
5 次引用
Journal of neurogastroenterology …
2024
4 次引用
Archivos argentinos de …
2024
3 次引用
Cureus
2024
1 次引用
Journal of translational …
2023
30 次引用
Nutrients
2023
19 次引用
Journal of neurogastroenterology …
2022
21 次引用
Journal of microbiology …
2022
15 次引用
Scientific reports
2022
14 次引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 次引用
Journal of clinical …
2015
62 次引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 次引用
Journal of clinical …
2012
207 次引用
PloS one
2012
31 次引用
Beneficial microbes
2011
89 次引用
The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.
Other
Neurogastroenterology and motility
2010
213 次引用
BMC gastroenterology
2010
91 次引用
Alimentary pharmacology & …
2007
102 次引用
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 次引用
Journal of clinical …
2004
205 次引用
Research in microbiology
2001
201 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 1-10 billion CFU/day
- adultgisupport:
- 5-10 billion CFU/day
- neonatalsupport:
- 1-5 billion CFU/day (as directed by pediatrician)
上限： Well-tolerated up to 10 billion CFU/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | 8 weeks | Positive | 1098 |
| None | 8 weeks | Neutral | 61 |
| 2 g | 4 weeks | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Serum-derived bovine immunoglobulin (SBI) | -- | Positive | -- |
| None | -- | Positive | -- |
最佳服用时间： Before meals or on empty stomach; for infants, mix with breast milk or formula
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools in infants (transient)
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 10 billion CFU/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Irritable Bowel Syndrome (IBS)
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。